Literature DB >> 12670918

Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma.

Andreas Bräuninger1, Hans-Heinrich Wacker, Klaus Rajewsky, Ralf Küppers, Martin-Leo Hansmann.   

Abstract

Hodgkin's lymphoma (HL) is separated into the classical (c) and lymphocyte-predominance (lp) forms. Whereas classical Hodgkin-Reed/Sternberg (HRS) cells carry mutated immunoglobulin (Ig) gene rearrangements that are often "crippled" and lack intraclonal diversity, and are likely derived from preapoptotic germinal center (GC) B cells, the lymphocytic and histiocytic cells of lpHL are presumably derived from selected GC B cells and often show ongoing somatic hypermutation. The recently identified lymphocyte-rich classical (lrc) HL is characterized by HRS cells with the immunophenotype of classical HRS cells (CD30(+)CD15(+)CD20(-)CD45(-)) but an infiltrate similar to lpHL and a clinical behavior resembling lpHL. To identify the histogenetic origin of the HRS cells in lrcHL and to determine the relationship to the lymphoma cells of cHL and lpHL we characterized seven cases of lrcHL by immunohistochemistry and sequenced the rearranged Ig genes of single micromanipulated HRS cells. The expression patterns of BCL6, CD138, Oct2, and BOB1 in HRS cells of lrcHL showed differences to those of both cHL and lpHL. Analyses of rearranged Ig genes identified clonal HRS cell expansions carrying mutated Ig rearrangements without significant intraclonal diversity in all seven of the cases. In two cases crippling mutations, rendering originally functional V gene rearrangements nonfunctional, were observed. Thus, the mutation pattern of rearranged Ig genes of HRS cells in lrcHL is clearly different from those in lymphocytic and histiocytic cells of lpHL, and resembles the pattern in HRS cells of cHL, suggesting that HRS cells in lrcHL derive from (preapoptotic) GC B cells that silenced hypermutation. In one case in addition to the dominant HRS cell clone, CD30(+) EBV-infected HRS-like cells unrelated to the tumor clone were observed, suggesting development of an expanded population of EBV-harboring HRS-like cells in the microenvironment of HL.

Entities:  

Mesh:

Year:  2003        PMID: 12670918

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  [Nodular lymphocyte-predominant Hodgkin's lymphoma and differential diagnoses].

Authors:  S Hartmann; S Cogliatti; M-L Hansmann
Journal:  Pathologe       Date:  2013-05       Impact factor: 1.011

Review 2.  Hodgkin lymphoma.

Authors:  Ralf Küppers; Andreas Engert; Martin-Leo Hansmann
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

3.  Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile.

Authors:  Johan H Gibcus; Lu Ping Tan; Geert Harms; Rikst Nynke Schakel; Debora de Jong; Tjasso Blokzijl; Peter Möller; Sibrand Poppema; Bart-Jan Kroesen; Anke van den Berg
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

Review 4.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

5.  MUM-1 expression differentiates AITL with HRS-like cells from cHL.

Authors:  Wenyong Huang; Jianlan Xie; Xiao Xu; Xue Gao; Ping Xie; Xiaoge Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 6.  The role of T cells in the microenvironment of Hodgkin lymphoma.

Authors:  Frederik Wein; Ralf Küppers
Journal:  J Leukoc Biol       Date:  2015-08-28       Impact factor: 4.962

7.  Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential.

Authors:  Philip Savage
Journal:  BMC Cancer       Date:  2015-01-21       Impact factor: 4.430

Review 8.  Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma.

Authors:  Christoph Renner; Frank Stenner
Journal:  Front Oncol       Date:  2018-06-04       Impact factor: 6.244

9.  Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma.

Authors:  Akio Sakatani; Takuro Igawa; Takeshi Okatani; Megumu Fujihara; Hideki Asaoku; Yasuharu Sato; Tadashi Yoshino
Journal:  J Clin Exp Hematop       Date:  2020-07-08

Review 10.  Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.

Authors:  Poonam Nagpal; Mohamed R Akl; Nehad M Ayoub; Tatsunari Tomiyama; Tasheka Cousins; Betty Tai; Nicole Carroll; Themba Nyrenda; Pritish Bhattacharyya; Michael B Harris; Andre Goy; Andrew Pecora; K Stephen Suh
Journal:  Oncotarget       Date:  2016-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.